Company: CNTB
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001835268-25-000052
Chunk: 5

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
8,773 5,348 15,406 14,011 General and administrative expense4,699 5,122 9,513 9,092 Total operating expenses13,472 10,470 24,919 23,103 (Loss) income from operations(13,424)13,646 (24,871)1,013 Other income, net:Interest income619 1,222 1,339 2,469 Other income (expense)(39)9 470 2,732 Total other income, net580 1,231 1,809 5,201 Net (loss) income before income tax(12,844)14,877 (23,062)6,214 Income tax expense55 30 109 60 Net (loss) income$(12,899)$14,847 $(23,171)$6,154 Other comprehensive (loss) income:Foreign currency translation adjustments236 79 298 (155)Unrealized (losses) gains on available-for-sale investments(6)2 (7)11 Comprehensive (loss) income$(12,669)$14,928 $(22,880)$6,010 Net (loss) income per ordinary share:Basic$(0.23)$0.27 $(0.42)$0.11 Diluted$(0.23)$0.27 $(0.42)$0.11 Weighted-average ordinary shares outstanding:Basic55,498 55,186 55,426 55,145 Diluted55,498 55,710 55,426 55,549 

See accompanying notes.

5

TABLE OF CONTENTS

CONNECT BIOPHARMA HOLDINGS LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(Unaudited)

(in thousands)

Ordinary SharesAdditional Paid-In CapitalAccumulated Other Comprehensive LossTreasuryAccumulatedDeficitTotal Shareholders' EquitySharesAmountSharesBalance, December 31, 202455,349$10 $439,357 $(1,666)$(180)$(345,355)$92,166 Issuance of ordinary shares upon exercise of stock options3 — 2 — — — 2 Share-based compensation expense— — 942 — — — 942 Net loss— —